中国神经再生研究(英文版) ›› 2018, Vol. 13 ›› Issue (4): 737-741.doi: 10.4103/1673-5374.230301

• 原著:退行性病与再生 • 上一篇    下一篇

血红素加氧酶1参与α-7烟碱乙酰胆碱受体激动剂保护早期亨廷顿病

  

  • 收稿日期:2018-01-30 出版日期:2018-04-15 发布日期:2018-04-15

Alpha-7 nicotinic acetylcholine receptor agonist treatment in a rat model of Huntington’s disease and involvement of heme oxygenase-1

Laura Foucault-Fruchard1, 2, Claire Tronel1, Sylvie Bodard1, Zuhal Gulhan1, Julie Busson1, Sylvie Chalon1, Daniel Antier1, 2   

  1. 1 UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
    2 CHRU de Tours, Hôpital Bretonneau, Tours, France
  • Received:2018-01-30 Online:2018-04-15 Published:2018-04-15
  • Contact: Laura Foucault-Fruchard,Ph.D.,laura.foucault@univ-tours.fr.
  • Supported by:

    This work was supported by the Région Centre-Val de Loire (2014 00094049 – AP 2014-850) and the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n°278850 (INMiND)

摘要:

我们最近研究发现,α-7烟碱乙酰胆碱受体(α7nAChR)激动剂PHA 543613的重复干预可对喹啉酸损伤的大鼠神经元有保护作用。为进一步探寻其作用机制,实验以右侧纹状体注射喹啉酸的方式建立早期亨廷顿病大鼠模型,然后随机给予其腹腔注射12 mg/kg PHA 543613或无菌水,2次/d,共4d。免疫印迹检测结果显示,相较于腹腔注射无菌水的对照大鼠,PHA 543613干预4d的亨廷顿病模型大鼠右侧纹状体胆碱能抗炎通路的关键组分血红素加氧酶1蛋白表达明显升高,且该作用独立于α7nAChR表达的变化。提示血红素加氧酶1表达与α7nAChR密度的增加无关。血红素加氧酶1表达的增加似乎是在早期亨廷顿病条件下观察到的与α7nAChR激活相关的神经保护作用的基础。

orcid:0000-0002-8037-9457(Laura Foucault-Fruchard)

关键词: 限速酶, 烟碱受体, PHA 543613, 喹啉酸, 胆碱能抗炎通路, 神经炎症, 神经退行性病变

Abstract:

Neuroinflammation is a common element involved in the pathophysiology of neurodegenerative diseases. We recently reported that repeated alpha-7 nicotinic acetylcholine receptor (α7nAChR) activations by a potent agonist such as PHA 543613 in quinolinic acid-injured rats exhibited protective effects on neurons. To further investigate the underlying mechanism, we established rat models of early-stage Huntington’s disease by injection of quinolinic acid into the right striatum and then intraperitoneally injected 12 mg/kg PHA 543613 or sterile water, twice a day during 4 days. Western blot assay results showed that the expression of heme oxygenase-1 (HO-1), the key component of the cholinergic anti-inflammatory pathway, in the right striatum of rat models of Huntington’s disease subjected to intraperitoneal injection of PHA 543613 for 4 days was significantly increased compared to the control rats receiving intraperitoneal injection of sterile water, and that the increase in HO-1 expression was independent of change in α7nAChR expression. These findings suggest that HO-1 expression is unrelated to α7nAChR density and the increase in HO-1 expression likely contributes to α7nAChR activation-related neuroprotective effect in early-stage Huntington’s disease.

Key words: alpha 7 nicotinic receptor, PHA 543613, quinolinic acid, cholinergic anti-inflammatory pathway, neuroinflammation, neurodegenerative disease